Japanese Drug Makers Build Stockpiles Against Impact Of Flu Pandemic
This article was originally published in PharmAsia News
Japanese pharmaceuticals are gearing up to add to drug stockpiles to ensure the country has two-month supplies of several drugs in case production is affected by an influenza pandemic. Mitsubishi Tanabe Pharma is creating a three-month stockpile of its blood products and treatments to treat strokes and newborn breathing problems. Eisai and Takeda are working on two-month supplies of their core products, which include Alzheimer's and cancer drugs for Eisai. Takeda is concentrating on in-demand drugs such as those for blood pressure, diabetes and prostate cancer. (Click here for more - a subscription may be required
You may also be interested in...
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.